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We present an adult female patient who developed irrever-
sible paraplegia and areflexia four days post intrathecal
chemotherapy with methotrexate, cytosine arabinoside and
hydrocortisone. On magnetic resonance imaging (MRI) of the
lumbar spine, diffuse gadolinium enhancement of the anterior
spinal nerve roots (ventral roots) was detected. Methylpre-
dnisolone was intravenously administered at a daily dose of
30 mg/kg for three days. Despite this treatment, flaccid weak-
ness in the lower extremities and urinary retention persisted.
Following consolidation chemotherapy, no improvement in
neurologic status was noted. Six months later, a follow-up
MRI revealed severe atrophy of the thoracic spinal cord.
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INTRODUCTION
A standard approach for central nervous system
(CNS) prophylaxis in patients with acute lym-
phoblastic leukemia (ALL) is the use of intrathecal
chemotherapy with methotrexate (MTX) or cyto-
sine arabinoside (Ara-C).
1
More patients are surviving ALL; and com-
plications have accordingly increased in number
due to the adverse effects of intrathecal chemo-
therapy. Chemical arachidonitis, myelopathy and
leukoencephalopathy are the most common
adverse effects of intrathecal chemotherapy.
However, to our knowledge studies have reported
fewer incidents of myelopathy following intra-
thecal chemotherapy in adult patients with ALL
than in their pediatric counterparts.
2,3
We recently encountered a case of ALL in
remission in which irreversible paraplegia was
noted after a single dose of prophylactic intra-
thecal chemotherapy with MTX, Ara-C and
hydrocortisone. We evaluated the clinical, MRI
and electrodiagnostic findings in this case.
CASE REPORT
A 25-year-old female patient was admitted in
February of 2004, complaining of generalized easy
bruising and weakness. Initial CBC showed
bicytopenia: Hb 4.8 g/dL, platelets 21,000/ L and μ
WBC 14,280/ L (75% blasts). An immunophe μ -
notype was characterized by the expression of
CD19 (89%) and CD22 (83.3%), in which HLA-DR
(94%) and CD34 (99%) were strong. A bone
marrow examination showed approximately 90%
small-to-medium sized blasts with a small amount
of blue cytoplasm.
In a chromosomal analysis of the bone marrow
a 46, XX karyotype was found in 100% (20/20).
RT-PCR analysis was negative for Bcr/Abl rea-
rrangement. Based on these findings, we made the
diagnosis of precursor B-cell ALL in our patient.
Induction chemotherapy of the VPDL regimen
consisted of 2 mg intravenous vincristine on days
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1, 8, 15 and 22; 60 mg/m
2 prednisolone on days
1 through 14; 45 mg/m
2 intravenous daunorubicin
on days 1 to 3; and 4,000 units/m
2 intramuscular
L-asparaginase on days 17 to 28. On day 42, bone
marrow examination showed complete hemato-
logic remission was achieved.
On day 43, our patient received prophylactic
intrathecal chemotherapy via lumbar puncture.
This consisted of preservative-free 12 mg MTX, 40
mg cytarabine and 50 mg hydrocortisone. Four
days later, she was noted to have leg weakness,
and symptoms progressed to the point that she
could not walk. In addition, the patient could not
move her legs without gravity. She had no deep
tendon reflexes over her patellae or ankles, and
exhibited a mild sensory deficit. We examined the
first CSF cytology concurrently with the pro-
phylactic intrathecal chemotherapy, and identified
atypical lymphocytes which were suspected to be
blasts. On the second, third and fourth CSF
cytologies however; no leukemic involvement was
evidenced. No further intrathecal chemotherapy
was given to the patient. Electromyography (EMG)
and nerve conduction velocity (NCV) studies
were consistent with the presence of myelopathy
and neuropathy in the motor and left median
axons. On magnetic resonance imaging (MRI) of
the lumbar spine, diffuse gadolinium enhancement
of the anterior roots (ventral roots) was detected
(Fig. 1). Methylprednisolone was administered at
a daily dose of 30 mg/kg for three days, however
lower extremity weakness and urinary retention
persisted. Eight months after the first MRI scan,
following nine cycles of consolidation chemo-
therapy, a follow-up T-2 weighted MRI image was
taken. This revealed heterogeneous high intensity
lesions in the thoracic spinal cord, in addition to
severe atrophy (Fig. 2). The patient was in
complete hematologic remission and was given
oral MTX, 6-mercaptopurine and prednisolone for
maintenance chemotherapy. However she demon-
strated no improvement in her paraplegia and
areflexia 18 months following the first signs of
irreversible paraplegia.
DISCUSSION
Intrathecal chemotherapy with MTX, Ara-C, or
both with or without hydrocortisone is considered
the standard of care for prophylaxis and treatment
of CNS leukemia and lymphoma.
1
According to several studies, intrathecal chemo-
therapy with MTX or Ara-C can lead to parap-
legia, with accompanying encephalopathy in
certain cases.
2-18
Little is known about the mechanism by which
intrathecal chemotherapy causes neurologic com-
plications. Speculation suggests they are related to
the neurotoxicity of MTX per se, or preservatives
added as a diluent. A local depletion of folate
secondary to MTX therapy or a high CSF level of
MTX might also be attributable factors.
19-21
Additionally, Ara-C has a longer half-life in the
CSF as compared to plasma. This property is
Fig. 2. Sagittal MRI showing heterogeneous high intensity
lesions in the thoracic spinal cord.
Fig. 1. Sagittal MRI of the lumbar spine showing diffuse
gadolinium enhancement of the anterior roots.IT CT Related Myelopathy in Adult ALL
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related to the lowered activity of Ara-C deaminase
in the CSF and the spinal cord, and may further
explain the neurotoxicity of Ara-C.
Intrathecal chemotherapy with MTX and Ara-C
could in theory cause myelopathy, although this
was rarely reported in adult patients with ALL.
22
In existing literature, patients had a history of
multiple intrathecal MTX injections (5-53 times)
prior to developing paraplegia. The range for a
single intrathecal dose of MTX was 5-25 mg. The
limiting cumulative dose varied from 90 and 305
mg.
8 However, irreversible paraplegia occurred
after a single dose of intrathecal chemotherapy in
our patient.
Literature suggests that the concomitant use of
intravenous or intrathecal Ara-C with intrathecal
MTX may enhance the neurotoxicity of MTX. The
dosage range of Ara-C in concomitant use with
intrathecal MTX is usually 30-170 mg, while the
toxic cumulative dose of Ara-C ranges between 40
and 780 mg.
8
To provoke the potential lymphotoxic effect as
well as to reduce arachnoiditis and other infla-
mmations of the CNS, hydrocortisone is often
administered concomitantly with intrathecal MTX
or Ara-C. However, to date no studies have
proven that concomitant use of hydrocortisone
prevents myelopathy.
23
In this case concomitant usage of Ara-C with
MTX was the lone precipitating factor. Neuro-
pathologic findings of myelopathy following
intrathecal chemotherapy typically include de-
myelination, microvacuolization and scattered
axonal swelling in the spinal cord.
6,18,23,24 In cases
of myelopathy, MRI is the most sensitive dia-
gnostic modality for detection of signal abnor-
malities of the spinal cord.
In cases of myelopathy following intrathecal
chemotherapy, treatment choices are made in a
limited scope. However, it is always imperative to
cease further intrathecal chemotherapy.
Myelopathy following intrathecal chemotherapy
is a rare but disastrous complication, and the
mechanism involved is not clearly understood. In
the management of adult patients with ALL
physicians must make a diagnosis of exclusion,
ruling out other potential etiologies such as
infection or leptomeningeal seeding.
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